# Temsirolimus and Irinotecan for Treatment Resistant Patients With Metastatic Colorectal Cancer and KRAS Mutations

> **NCT00827684** · PHASE2 · COMPLETED · sponsor: **Vejle Hospital** · enrollment: 50 (estimated)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Irinotecan
- **DRUG:** Temsirolimus

## Key facts

- **NCT ID:** NCT00827684
- **Lead sponsor:** Vejle Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03
- **Primary completion:** 2011-01
- **Final completion:** 2011-06
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2011-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00827684

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00827684, "Temsirolimus and Irinotecan for Treatment Resistant Patients With Metastatic Colorectal Cancer and KRAS Mutations". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00827684. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*